Oncology & Cancer

Pediatric cancers have unique genetic vulnerabilities

Most cancer drugs that target specific genetic mutations are designed for adult cancers rather than those in children, partly because pediatric cancers have fewer mutations. To look for more ways to target childhood cancers, ...

Oncology & Cancer

Origin of childhood cancer malignant rhabdoid tumour discovered

The first proof of the origin of malignant rhabdoid tumor (MRT), a rare childhood cancer, has been discovered by researchers at the Wellcome Sanger Institute, the Princess Máxima Center for Pediatric Oncology in the Netherlands, ...

Oncology & Cancer

A need for experts in pediatric onco-nephrology

The need for pediatric nephrologists to develop a special expertise in the onco-nephrology field is increasingly important as childhood cancer rates have been on the rise and new therapy protocols are advancing, according ...

Oncology & Cancer

New drug targets for childhood cancer neuroblastoma identified

The largest single cell study to date of the childhood cancer, neuroblastoma, has answered important questions about the genesis of the disease. The researchers from the Wellcome Sanger Institute, Great Ormond Street Hospital ...

Oncology & Cancer

Brain tumor drug receives rare disease designations from the FDA

The U.S. Food and Drug Administration has awarded Rare Pediatric Disease Designation (RPDD) for diffuse intrinsic pontine glioma (DIPG) and Orphan Drug Designation for treatment of malignant glioma to OKN-007, an investigational ...

page 7 from 21